Catalent Releases a Corporate Responsibility Report for Fiscal 2019
The report outlines the company’s approaches to product quality, safety, environmental sustainability, and diversity and inclusion.
On April 14, 2020, Catalent published its first Corporate Responsibility (CR) Reportfor the fiscal year 2019.
According to a company press release, the report outlines the company’s approaches to product quality, safety, environmental sustainability, and diversity and inclusion. Specific points mentioned include Catalent’s global accreditation under ISO 14001 and the Occupational Health and Safety Assessment Series 18001, the establishment of a goal to reduce its carbon emissions by 15 percent by 2023 by investing in energy efficiency and renewable energy, the company’s introduction of additional volunteer programs, and its commitment to fostering a more inclusive workplace by signing a CEO Action for Diversity and Inclusion pledge.
“Responsible business practices reflect our deep commitment to our mission and values,” said John Chiminski, Catalent’s chair and CEO, in the press release. “This report communicates our CR priorities and progress at an enterprise level, demonstrating Catalent’s ongoing commitment to long-term value-creation and sustainability by investing in people, the environment, and our communities.”
Source: Catalent
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
